Yüklüyor......
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Russo |
| Baskı/Yayın Bilgisi: |
ABV-press
2021-09-01
|
| Seri Bilgileri: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| Konular: | |
| Online Erişim: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|